Cellistic Unveils Allo Chassis™: Immune-Cloaked iPSC Cell Lines for Cost-Effective Cell Therapy
Cellistic, a leader in iPSC-based off-the-shelf cell therapy development and manufacturing services, has introduced its innovative Allo Chassis™—a new line of immune-cloaked iPSC cell lines derived from CD34+ and CD4+ T-cell primary cells. This breakthrough product is designed to significantly reduce development timelines and costs for cell therapy developers, making it easier and more efficient to bring therapies to market. With Allo Chassis™, Cellistic is pushing the boundaries of cell line development by offering ready-to-use, immune-modified cell lines that set a new standard in the rapidly evolving cell therapy space.
At the core of Cellistic’s mission is a commitment to increasing global accessibility to cell therapies by leveraging the power of induced pluripotent stem cells (iPSCs). By developing the Allo Chassis™ cell lines, Cellistic provides a valuable resource to therapeutic developers, enabling them to expedite the development process while cutting down on the financial barriers that often hinder progress.
This is especially important as the demand for more efficient, cost-effective treatments continues to grow in the biopharmaceutical industry. These new iPSC cell lines are immune-cloaked, which means they are specifically designed to evade the recipient’s immune system, a critical step in developing universally applicable cell therapies that can be used in a broad range of patients without the need for individualized treatments.
The Allo Chassis™ cell lines offer iPSCs derived from both CD34+ and CD4+ T-cell primary cells, making them versatile tools for various cell therapy applications. These off-the-shelf products are already edited using Cellistic’s proprietary STAR-CRISPR™ gene editing technology, providing partners with a robust platform for advanced gene editing and a clear route for intellectual property licensing.
With these gene-edited cell lines, developers have access to material that is compatible with most therapeutic applications, giving them a head start in producing high-quality, clinically ready therapies. Cellistic’s adherence to current Good Manufacturing Practice (cGMP) standards ensures that the Allo Chassis™ cell lines are produced using validated workflows, rigorous quality controls, and cutting-edge automation, ensuring their consistency and reliability.
Stefan Braam, Founder and Chief Technology Officer (CTO) of Cellistic, highlighted the core advantages of the Allo Chassis™ cell lines, saying, “Allo Chassis™ provides therapeutic developers with iPSC starting material featuring the most commonly used gene modifications, resulting in the deletion of HLA class I and II.
These off-the-shelf cell lines can be efficiently customized using our STAR-CRISPR™ gene editing technology, enabling rapid creation of product-specific master cell banks at a significantly reduced cost.” The deletion of HLA class I and II is particularly important because it prevents immune rejection, making the Allo Chassis™ cell lines more universally applicable for all patients regardless of their individual genetic makeup.
The new immune-cloaked CD34+ and CD4+ T-cell derived iPSC cell banks are available immediately for researchers and developers looking to advance their therapeutic programs. This represents a major step forward in making advanced cell therapies more accessible and cost-effective, aligning with Cellistic’s mission to streamline the path to clinical application. The ability to provide off-the-shelf cell lines also dramatically shortens the time required to develop cell-based therapies, which traditionally involves lengthy and expensive processes to generate suitable starting materials.
Cellistic’s STAR-CRISPR™ gene editing technology is a critical component of the Allo Chassis™ offering. This proprietary tool allows for precise, efficient gene editing that can be used to tailor the iPSC cell lines to meet the specific needs of different therapies. The flexibility of STAR-CRISPR™ enables researchers to make customized modifications quickly, accelerating the development of new treatments while maintaining high standards of safety and efficacy.
The Allo Chassis™ cell lines are an ideal resource for companies developing next-generation cell therapies, particularly those focused on immune cell therapies, which often require advanced gene editing and customized starting materials. By providing high-quality, off-the-shelf immune-modified iPSCs, Cellistic is helping to lower the barriers to developing cell therapies that can address a wide range of diseases, including cancer, autoimmune disorders, and other complex conditions.
Cellistic’s commitment to supporting cell therapy developers is evident in its ongoing efforts to improve the accessibility and efficiency of cell-based treatments. By leveraging more than a decade of scientific and technical expertise, the company has positioned itself as a leader in iPSC-based technology. Through its Pulse™ and Echo™ platforms, Cellistic continues to advance the field of cell therapy, providing partners with state-of-the-art solutions that drive innovation and improve patient outcomes.
In conclusion, the launch of the Allo Chassis™ cell lines marks a major milestone for Cellistic, offering a powerful tool for therapeutic developers seeking to create cost-effective, scalable cell therapies. With immune-cloaked iPSCs derived from CD34+ and CD4+ T-cells, gene-edited using the company’s proprietary STAR-CRISPR™ technology, and produced to meet cGMP standards, the Allo Chassis™ platform sets a new benchmark for the future of cell therapy development. As the biopharmaceutical industry continues to push forward with new, innovative treatments, Cellistic’s Allo Chassis™ offers a promising solution to the challenges of developing and commercializing cell therapies at scale.
